<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01617369</url>
  </required_header>
  <id_info>
    <org_study_id>11-1932</org_study_id>
    <nct_id>NCT01617369</nct_id>
  </id_info>
  <brief_title>Study to Characterize the Durability of Hypertonic Saline to Enhance Mucociliary Clearance in Healthy Subjects</brief_title>
  <official_title>A Study to Characterize the Durability of Hypertonic Saline for the Enhancement of Mucociliary Clearance in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of North Carolina, Chapel Hill</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to learn about how long hypertonic saline (HS) works in
      healthy subjects. Inhaled hypertonic saline is one of the medications used to treat Cystic
      Fibrosis (CF). In CF and more common lung diseases like chronic bronchitis, mucus builds up
      in the lungs. Hypertonic saline and other medications currently being developed may help
      patients with these lung diseases by speeding up mucus clearance from the lung. For these
      treatments to be effective, they likely need to be able to act for at lease several hours.
      Investigators are able to measure how lung treatments like hypertonic saline work by
      conducting a Mucociliary Clearance (MCC) scan. Currently, the investigators do not know how
      long hypertonic saline works in people who do not have CF. Investigators plan to use this
      information to improve the design and testing of new treatments for patients with chronic
      bronchitis.

      Objectives:

        1. The investigators will use MCC measurements to determine the durability of action of
           hypertonic saline in healthy (i.e. non-CF) subjects.

        2. The investigators will determine the intra- and inter-individual variability of baseline
           MCC measurements using a slow inhalation/large particle protocol in healthy subjects to
           guide future sample size calculations.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Subjects completed mucociliary clearance measurements (via gamma scintigraphy) at baseline, 30 minutes after inhaling 2.8% NaCl, and 4 hours after inhaling 2.8% NaCl at separate study visits to characterize acute vs. sustained effects of inhaled 2.8% NaCl on this physiologic process.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Whole Lung Mucociliary Clearance</measure>
    <time_frame>30 minutes and 4 hours after inhalation</time_frame>
    <description>The primary outcome of mucociliary clearance (MCC) will be depicted by calculating the average rate of isotope clearance (%) from the whole lung compartment, measured for 90 minutes after isotope inhalation (MCC-Ave 90), using data points collected every 10 minutes.
Absolute change in MCC-Ave90 from baseline reported for each arm</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>Acute Hypertonic Saline Effect</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2.8% NaCl inhaled 30 minutes before Mucociliary Clearance measured.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sustained Hypertonic Saline Effect</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2.8% NaCl inhaled 4 hours before Mucociliary Clearance measured.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Hypertonic Saline</intervention_name>
    <description>2.8% NaCl x 4ml via nebulizer</description>
    <arm_group_label>Acute Hypertonic Saline Effect</arm_group_label>
    <arm_group_label>Sustained Hypertonic Saline Effect</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy subjects, without respiratory or cardiac comorbidities

          -  Age 18-55 years, inclusive

          -  FEV1 &gt; 80% predicted and FEV1/FVC ratio &gt;70%

          -  Non-pregnant female subjects must be either not sexually active, post-menopausal,
             surgically sterilized, or agree to use an appropriate &quot;double-barrier&quot; method (such as
             a diaphragm and condom); or, must currently be using a prescribed transdermal,
             injection, implant, or oral contraceptive during study participation

          -  Subjects who are capable of providing their written informed consent to participate in
             the study

        Exclusion Criteria:

          -  History of smoking &gt; 10 pack-years

          -  Any history of smoking within 60 days of screening

          -  Acute upper or lower respiratory illness within 30 days of screening

          -  Respiratory medication for any indication within 30 days of screening

          -  History of asthma, chronic bronchitis, or other chronic lung disease

          -  History of intolerance to hypertonic saline

          -  Women who are pregnant, lactating, or of childbearing potential who are unwilling to
             use an acceptable method of contraception throughout the duration of the study.

          -  Any condition that, in the opinion of the investigator, would potentially jeopardize
             the safety of the participant or the integrity of the study

          -  History of radiation exposure within the past year that would cause the subject to
             exceed limits for adults established by Federal Regulations

          -  Subjects who, in the opinion of the Principal Investigator, should not participate in
             the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott Donaldson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of North Carolina, Chapel Hill</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of North Carolina at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 6, 2012</study_first_submitted>
  <study_first_submitted_qc>June 11, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 12, 2012</study_first_posted>
  <results_first_submitted>February 15, 2017</results_first_submitted>
  <results_first_submitted_qc>February 15, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 4, 2017</results_first_posted>
  <last_update_submitted>April 28, 2017</last_update_submitted>
  <last_update_submitted_qc>April 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of North Carolina, Chapel Hill</investigator_affiliation>
    <investigator_full_name>Scott Donaldson, MD</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Hypertonic Saline</title>
          <description>2.8% NaCl
Hypertonic Saline: 2.8% NaCl x 4ml via nebulizer</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Healthy subjects of any ethnicity between 18-55 years of age, without respiratory or cardiac comorbidities, FEV1 greater than or equal to 80% predicted, FEV1/FVC ratio greater than 70%, non-pregnant female subjects, and subjects who are capable of providing their written informed consent.</population>
      <group_list>
        <group group_id="B1">
          <title>Hypertonic Saline</title>
          <description>2.8% NaCl
Hypertonic Saline: 2.8% NaCl x 4ml via nebulizer</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.5" lower_limit="20" upper_limit="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>East Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black/African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>West Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other, Specify</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Current Smoker</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Whole Lung Mucociliary Clearance</title>
        <description>The primary outcome of mucociliary clearance (MCC) will be depicted by calculating the average rate of isotope clearance (%) from the whole lung compartment, measured for 90 minutes after isotope inhalation (MCC-Ave 90), using data points collected every 10 minutes.
Absolute change in MCC-Ave90 from baseline reported for each arm</description>
        <time_frame>30 minutes and 4 hours after inhalation</time_frame>
        <population>Per Protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Acute Hypertonic Saline Effect</title>
            <description>2.8% NaCl inhaled 30 minutes before MCC scan performed
Hypertonic Saline: 2.8% NaCl x 4ml via Pari LC STAR jet nebulizer</description>
          </group>
          <group group_id="O2">
            <title>Sustained Hypertonic Saline Effect</title>
            <description>2.8% NaCl Inhaled 4 hours before mucociliary clearance measured
Hypertonic saline = 2.8% NaCl x 4 ml delivered via Pari LC STAR jet nebulizer</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Whole Lung Mucociliary Clearance</title>
          <description>The primary outcome of mucociliary clearance (MCC) will be depicted by calculating the average rate of isotope clearance (%) from the whole lung compartment, measured for 90 minutes after isotope inhalation (MCC-Ave 90), using data points collected every 10 minutes.
Absolute change in MCC-Ave90 from baseline reported for each arm</description>
          <population>Per Protocol</population>
          <units>% Clearance</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="6.4"/>
                    <measurement group_id="O2" value="-4.0" spread="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Paired t-test performed. Null hypothesis is that no difference in clearance 30 min and 4 hr after HS inhalation exists</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;.05</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Acute Hypertonic Saline Effect</title>
          <description>2.8% NaCl inhaled 30 minutes before Mucociliary Clearance measured.
Hypertonic Saline: 2.8% NaCl x 4ml via nebulizer</description>
        </group>
        <group group_id="E2">
          <title>Sustained Hypertonic Saline Effect</title>
          <description>2.8% NaCl inhaled 4 hours before Mucociliary Clearance measured.
Hypertonic Saline: 2.8% NaCl x 4ml via nebulizer</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Scott Donaldson</name_or_title>
      <organization>University of North Carolina Chapel Hill</organization>
      <phone>919-966-9198</phone>
      <email>scott_donaldson@med.unc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

